14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for ALT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 7.81 7.03 %
R2 7.65 4.73 %
R1 7.54 3.31 %
Current price: 7.30
Support S1 7.21 -1.30 %
S2 7.10 -2.72 %
S3 6.93 -5.02 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 8.89 21.78 %
R2 8.46 15.89 %
R1 8.40 15.07 %
Current price 7.30
Support S1 7.07 -3.15%
S2 7.04 -3.56%
S3 6.40 -12.40%

ALT Predictions History

4 years ago
JS predicted that ALT for 2020-04-02 is going $2.94 (-2.65%)

4 years ago
Justin Moore predicted that ALT for 2020-04-02 is going

Rank:

4 years ago
2poJeff predicted that ALT for 2020-04-02 is going $3.00 (-1.32%)

4 years ago
JS predicted that ALT for 2020-03-27 is going $3.09 (8.42%)

4 years ago
Erique Zuniga predicted that ALT for 2020-03-27 is going

Rank:

5 years ago
PumpTheseNumbers predicted that ALT for 2019-04-03 is going $3.14 (1.95%)

5 years ago
JS predicted that ALT for 2019-04-03 is going $2.98 (-3.25%)

5 years ago
Jacob.Peak.106264 predicted that ALT for 2019-04-03 is going $3.07 (2.33%)

Rank:

5 years ago
Andrew.Schodrof.106253 predicted that ALT for 2019-04-03 is going $2.00 (-33.33%)

Rank:

5 years ago
ss predicted that ALT for 2019-04-03 is going $3.43 (14.33%)

Rank:
Click to get the best stock tips daily for free!

About Altimmune, Inc.

Altimmune. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica... ALT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT